Drug Profile
Research programme: ophthalmic infections therapeutics - CLS Pharmaceuticals
Alternative Names: CLSA 1506Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator CLS Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Ophthalmic infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Ophthalmic-infections in USA (Topical)
- 14 Feb 2008 Preclinical trials in Ophthalmic infections in USA (Topical)